Cardiff Oncology Sues Partner Over Lead Drug Patent Dispute, Escalating License Battle
CRDF sits 20% above its 52-week low of $1.48 on elevated volume (4.1× avg).
Summary
Cardiff Oncology has filed a lawsuit against Nerviano Medical Sciences (NMS) in U.S. District Court, seeking an injunction and denying NMS's claim of a material breach of their onvansertib license agreement. NMS alleges Cardiff failed to name an NMS employee on two U.S. patents. This legal action significantly escalates the "ongoing critical license dispute" for its lead drug, Onvansertib, which was previously disclosed in the company's Q1 2026 10-Q filing on May 14th. Given Cardiff's small market capitalization and the prior "going concern" warning, a legal battle over its core intellectual property introduces substantial financial and operational risk. Traders should closely monitor the lawsuit's developments, as its outcome could materially impact the company's valuation and the future of its lead drug program.
At the time of this announcement, CRDF was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $120.3M. The 52-week trading range was $1.48 to $4.56. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.